
Liquidity, historical trends, and peer comparisons.
According to Nuvectis Pharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.92. This represents a change of 144.06% compared to the average of 4.07 of the last 4 quarters.
The mean historical Current Ratio of Nuvectis Pharma, Inc. over the last ten years is 2.16. The current 9.92 Current Ratio has changed 360.33% with respect to the historical average. Over the past ten years (40 quarters), NVCT's Current Ratio was at its highest in in the June 2021 quarter at 18.54. The Current Ratio was at its lowest in in the March 2021 quarter at 0.
Average
2.16
Median
2.40
Minimum
0
Maximum
3.30
Discovering the peaks and valleys of Nuvectis Pharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Current Ratio = 3.30
Minimum Annual Increase = -23.84%
Minimum Annual Current Ratio = 0
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 2.38 | 13.99% |
| 2024 | 2.09 | -23.84% |
| 2023 | 2.75 | -16.72% |
| 2022 | 3.30 | 36.80% |
| 2021 | 2.41 | Infinity% |
The current Current Ratio of Nuvectis Pharma, Inc. (NVCT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.41
5-year avg
2.59
10-year avg
2.16
Nuvectis Pharma, Inc.’s Current Ratio is less than ORIC Pharmaceuticals, Inc. (13.19), greater than Nuvation Bio Inc. (8.37), less than Immix Biopharma, Inc. (25.13), greater than Syndax Pharmaceuticals, Inc. (4.69), greater than MacroGenics, Inc. (2.96), less than Immuneering Corporation (13.97), greater than Verastem, Inc. (2.25), less than Janux Therapeutics, Inc. (16.35), greater than Mereo BioPharma Group plc (5.88), less than Compass Therapeutics, Inc. (11.22),
| Company | Current Ratio | Market cap |
|---|---|---|
| 13.19 | $968.12M | |
| 8.37 | $1.66B | |
| 25.13 | $660.74M | |
| 4.69 | $933.15M | |
| 2.96 | $147.15M | |
| 13.97 | $243.51M | |
| 2.25 | $892.05M | |
| 16.35 | $1.11B | |
| 5.88 | $48.40M | |
| 11.22 | $137.35M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvectis Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nuvectis Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Nuvectis Pharma, Inc.'s Current Ratio?
How is the Current Ratio calculated for Nuvectis Pharma, Inc. (NVCT)?
What is the highest Current Ratio for Nuvectis Pharma, Inc. (NVCT)?
What is the 3-year average Current Ratio for Nuvectis Pharma, Inc. (NVCT)?
What is the 5-year average Current Ratio for Nuvectis Pharma, Inc. (NVCT)?
How does the current Current Ratio for Nuvectis Pharma, Inc. (NVCT) compare to its historical average?